Loading...
  • Hepatic
  • Antagonizing the glucagon signaling pathway represents an attractive therapeutic approach for reducing excess hepatic glucose production in patients with type 2 diabetes. (aspetjournals.org)
  • Blood Glucose
  • Objectives: To determine if glucagon is involved in mediating the increase in blood glucose levels caused by the second-generation antipsychotic drug olanzapine. (edu.au)
  • Glucagon-like peptide 1 (GLP1) is postulated to regulate blood glucose and satiety, but the biological importance of GLP1 as an incretin and neuropeptide remains controversal. (nih.gov)
  • diabetes
  • In recent years, several attempts to generate small molecules or antibodies that impair glucagon action have been pursued as potential therapeutics for type 2 diabetes. (diabetesjournals.org)
  • Our results demonstrate a new strategy for targeting the GPCRs and further support the concept of antagonizing the glucagon signaling pathway as a potential therapeutic approach for type 2 diabetes. (aspetjournals.org)
  • Antagonizing the glucagon signaling pathway represents an attractive therapeutic approach for the treatment of type 2 diabetes. (aspetjournals.org)
  • The present invention is directed to biphenyl derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity. (patentsencyclopedia.com)
  • en] INTRODUCTION: Despite type 2 diabetes (T2D) being recognized as a bihormonal pancreatic disease, current therapies are mainly focusing on insulin, while targeting glucagon has been long dismissed. (uliege.be)
  • clinical
  • Here, we place their success in perspective and discuss the advantages and concerns relating to glucagon-based therapeutics as this line of drugs comes closer than ever to achieving their clinical potential. (diabetesjournals.org)
  • amino
  • This glucose-raising peptide was termed "glucagon" ( 4 ) and subsequently purified and identified as a 29-amino acid peptide ( 5 ). (diabetesjournals.org)
  • Four years before the visit, the then 60-year-old female patient had presented with abdominal pain but without skin rash, hyperglycemia, weight loss, thromboembolism, or stomatitis, components of the glucagonoma syndrome which is an amino acid deficiency syndrome caused by high glucagon levels associated with glucagonoma [ 7 ]. (omicsonline.org)
  • Glucagon, a 29-amino acid peptide secreted by pancreatic α-cells, plays an important role in controlling endogenous glucose production. (aspetjournals.org)
  • The trinitrophenyl group was specifically introduced into the epsilon-amino group of glucagon by reaction of N alpha-citraconyl glucagon with trinitrobenzenesulfonic acid. (biomedsearch.com)
  • subsequently
  • The N alpha-citraconyl blocking group was subsequently removed by acid treatment yielding N epsilon-trinitrophenyl glucagon which was purified by anion-exchange chromatography. (biomedsearch.com)
  • Discovery
  • In addition to the discovery of insulin, the crew of Banting, Best, and Collip observed glucagon action, as they had noticed in their preclinical studies in canines that some of their crude insulin preparations would raise glucose levels in the dog briefly before glucose was lowered ( 2 , 3 ). (diabetesjournals.org)